Invitae Corporation (NYSE:NVTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02

Invitae Corporation today announced that Sean George, Ph.D., its
co-founder and current president and chief operating officer, has
been named chief executive officer for the company. Current
chairman and chief executive officer Randy Scott will become
executive chairman of the board of directors and remain full time
at the company. The appointments are effective immediately.

On January9, 2017, Invitae issued a press release with respect to
the companys new leadership structure. A copy of such press
release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.

2

About Invitae Corporation (NYSE:NVTA)

Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. The Company offers panels for over 120 conditions in hereditary cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. It has developed an offering that enables healthcare professionals to customize a test and receive test results at requisition.

Invitae Corporation (NYSE:NVTA) Recent Trading Information

Invitae Corporation (NYSE:NVTA) closed its last trading session up +0.43 at 8.97 with 646,701 shares trading hands.